NCT06763159View on ClinicalTrials.gov

A Study of HS-20124 in Patients with Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Solid Cancer
Interventions
DRUG

HS-20124 (Phase Ia：Dose escalation )

Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.

DRUG

HS-20124 (Phase Ib: Dose expansion)

Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.

Trial Locations (1)

201321

RECRUITING

Affiliated Cancer Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Hansoh BioMedical R&D Company

INDUSTRY